Yuan-Di Halvorsen, Ph.D.

Instructor in Investigation
Center for Computational and Integrative Biology, Mass General Research Institute
Lecturer on Medicine
Harvard Medical School
biologics; clinical development; drug development; quality assurance; regulations; research and development; small molecules; therapeutic development; translational medicine; translational research

Dr. Halvorsen joined the Translational Medicine program of the Center for Computational and Integrative Biology at MGH in 2007.

She has established the group’s core competencies in program management, regulatory and clinical operations, and implemented Quality Assurance systems within this academic enterprise.

By applying these management tools and leveraging the research and clinical knowledge of MGH faculty members, the Translational Medicine program has advanced multiple therapeutic development projects in an effective, efficient and economical manner.

Through her leadership, TMG has successfully advanced both small molecules and biologics from basic research discovery labs to the clinic.

These programs have ranged widely, including new therapies for diabetes, depression, respiratory papillomatosis, and anemia. Earlier stage programs in cholera vaccine development and stroke therapy are also ongoing.

Dr. Halvorsen also advises academic investigators and biotechnology companies on new drug development, including regulatory and clinical strategy. Prior to her work at the MGH, Dr. Halvorsen co-founded two biotechnology companies with platform technologies in cell-based therapy and led the clinical development of protein and antibody drugs for cancer and supportive care for cancer patients.

She served as Associate Director of Clinical Development at CuraGen Corporation, Vice President of Research at Artecel Sciences, and Vice President of Research & Development and President of Zen-Bio, Inc.

In addition, Dr. Halvorsen was an Adjunct Associate Professor at the University of North Carolina at Greensboro. She obtained her Ph.D. in Biochemistry at the University of Kentucky and received postdoctoral training at the Dana Farber Cancer Institute and Harvard Medical School.